Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEGEAN: Education and Guidance Programme for Eliquis Adherence in Non‑Valvular Atrial Fibrillation
2013-000055-41Phase 4Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of apixaban in Atrial fibrillation (AFib) and stroke (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Primary adherence endpoint at 24 weeks. Started Jun 2013; status: completed.
02
Drugs
apixaban
03
Conditions
Atrial fibrillation (AFib)stroke
Beyond the preview
Go deeper on 2013-000055-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000055-41.